Skip to content

Obinutuzumab

Gazyva, Gazyvaro (obinutuzumab) is an antibody pharmaceutical. Obinutuzumab was first approved as Gazyva on 2013-11-01. It is used to treat follicular lymphoma and lymphoid leukemia in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia. The pharmaceutical is active against B-lymphocyte antigen CD20.
Trade Name Gazyvaro
Common Name Obinutuzumab
Indication b-cell chronic lymphocytic leukemia, follicular lymphoma, lymphoid leukemia
Drug Class Monoclonal antibodies: humanized, tumors as target
Obinutuzumab
Get full access now